A mouse-model study published in Cell Death Discovery reports that long-term administration of the selective NMDA GluN2B antagonist Ro25-6981 attenuates neurodegeneration in spinocerebellar ataxia type 1 (SCA1). Researchers focused on sustained dosing effects, reporting a reduction in neurodegenerative outcomes compared with control conditions. The findings add to the growing interest in NMDA receptor subunit targeting for neurodegenerative disease, where translating pharmacology into durable benefits remains a key hurdle. The study’s emphasis on long-term treatment regimens highlights the need for chronic-intervention evidence in central nervous system indications.